266 related articles for article (PubMed ID: 33525371)
1. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery.
Ermondi G; Garcia-Jimenez D; Caron G
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525371
[TBL] [Abstract][Full Text] [Related]
2. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
3. Are we ready to design oral PROTACs®?
Jimenez DG; Sebastiano MR; Caron G; Ermondi G
ADMET DMPK; 2021; 9(4):243-254. PubMed ID: 35300370
[TBL] [Abstract][Full Text] [Related]
4. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
5. In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor.
Apprato G; D'Agostini G; Rossetti P; Ermondi G; Caron G
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770875
[TBL] [Abstract][Full Text] [Related]
6. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
7. PROTACs- a game-changing technology.
Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
[No Abstract] [Full Text] [Related]
8. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
9. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
10. New Frontiers in the Discovery and Development of PROTACs.
Barghout SH
Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
[TBL] [Abstract][Full Text] [Related]
11. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
12. Updating the portfolio of physicochemical descriptors related to permeability in the beyond the rule of 5 chemical space.
Ermondi G; Vallaro M; Goetz G; Shalaeva M; Caron G
Eur J Pharm Sci; 2020 Apr; 146():105274. PubMed ID: 32088315
[TBL] [Abstract][Full Text] [Related]
13. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
14. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
15. Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform.
Guo L; Liu J; Nie X; Wang T; Ma ZX; Yin D; Tang W
Bioorg Med Chem Lett; 2022 Nov; 75():128982. PubMed ID: 36096343
[TBL] [Abstract][Full Text] [Related]
16. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
17. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
18. Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation.
Gross PH; Sheets KJ; Warren NA; Ghosh S; Varghese RE; Wass KWass KE; Kadimisetty K
Biochem Biophys Res Commun; 2022 Nov; 628():68-75. PubMed ID: 36084553
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation.
Chen Y; Tandon I; Heelan W; Wang Y; Tang W; Hu Q
Chem Soc Rev; 2022 Jul; 51(13):5330-5350. PubMed ID: 35713468
[TBL] [Abstract][Full Text] [Related]
20. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C
Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]